<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>First-trimester pregnancy termination: Uterine aspiration</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">First-trimester pregnancy termination: Uterine aspiration</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">First-trimester pregnancy termination: Uterine aspiration</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Grace Shih, MD, MAS</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robin Wallace, MD, MAS</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Cassing Hammond, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alana Chakrabarti, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 14, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1482582147"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Termination of pregnancy by uterine aspiration (also known as aspiration curettage, suction curettage, dilation and curettage, or procedural abortion) is a commonly used method of abortion. It is typically used in the first trimester through 13 6/7 weeks of gestation, though it can be performed by some providers through approximately 15 6/7 weeks gestation. Uterine aspiration is an alternative to medication abortion (also referred to as medical abortion or induction abortion).</p><p>First-trimester uterine aspiration is reviewed here. An overview of pregnancy termination, including a discussion on how to choose between a medication and aspiration abortion, as well as first-trimester medication abortion and management of second-trimester pregnancy terminations, is discussed elsewhere. </p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3313.html" rel="external">"Overview of pregnancy termination"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3296.html" rel="external">"First-trimester pregnancy termination: Medication abortion"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/14194.html" rel="external">"Overview of second-trimester pregnancy termination"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/90163.html" rel="external">"Second-trimester pregnancy termination: Induction (medication) termination"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/104595.html" rel="external">"Second-trimester pregnancy termination: Dilation and evacuation"</a>.)</p><p></p><p class="headingAnchor" id="H2397848797"><span class="h1">PATIENT SELECTION</span><span class="headingEndMark"> — </span>Uterine aspiration is commonly performed through 14 weeks of gestation, though some clinicians offer uterine aspiration in the second trimester.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Counseling</strong> – Patients choosing first-trimester uterine aspiration are counseled about the alternatives (ie, continuing pregnancy with parenting or adoption) and the choice between medication and aspiration abortion, including the risks, benefits, and expected outcomes of each [<a href="#rid1">1-4</a>]. This is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/114587.html" rel="external">"Counseling in abortion care"</a> and  <a class="medical medical_review" href="/z/d/html/3313.html" rel="external">"Overview of pregnancy termination"</a>.)</p><p></p><p class="bulletIndent1">Many states have regulations and restrictions regarding abortion care [<a href="#rid5">5</a>]. Clinicians should be aware of their state and federal guidelines. (See  <a class="medical medical_review" href="/z/d/html/114587.html" rel="external">"Counseling in abortion care"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Contraindications</strong> – There are few absolute contraindications to first-trimester aspiration abortion, which include inability to obtain informed consent and selected anatomic conditions (eg, fibroids that restrict access to the uterine cavity). </p><p></p><p class="bulletIndent1">Medical conditions that increase risk of complications with first-trimester abortion also increase the risk of a continued pregnancy. Thus, when abortion is desired in a patient with comorbidities, the relative increased risk of abortion must be compared with the increased risk if pregnancy were to continue.</p><p></p><p class="bulletIndent1">Low-grade fever (≤100.4°F, or 38°C) and uterine tenderness are <strong>not</strong> contraindications to aspiration abortion [<a href="#rid6">6-9</a>]. For higher fevers or if clinically significant infection is suspected, the clinician should evaluate for septic abortion. (See  <a class="medical medical_review" href="/z/d/html/130878.html" rel="external">"Septic abortion: Clinical presentation and management", section on 'Evaluation'</a>.)</p><p></p><p class="headingAnchor" id="H909421247"><span class="h1">PREPROCEDURE EVALUATION AND PREPARATION</span></p><p class="headingAnchor" id="H1507016619"><span class="h2">History</span><span class="headingEndMark"> — </span>Clinicians should elicit a standard medical history. Particular attention should be given to any report of bleeding or clotting disorders, anemia, or uterine/cervical abnormalities.</p><p class="headingAnchor" id="H3570360882"><span class="h2">Physical examination and ultrasound</span><span class="headingEndMark"> — </span>Physical examination includes:</p><p class="bulletIndent1"><span class="glyph">●</span>Vital signs</p><p class="bulletIndent1"><span class="glyph">●</span>Gestational age estimated by uterine size on pelvic examination</p><p class="bulletIndent1"><span class="glyph">●</span>Uterine flexion assessment by pelvic examination </p><p class="bulletIndent1"><span class="glyph">●</span>Cardiac, pulmonary, and airway assessment for patients in whom moderate or deep sedation is planned</p><p></p><p>If uterine size on physical examination is inconsistent with the expected gestational age (based on the first day of the last menstrual period), ultrasound may increase the accuracy of the gestational estimation and evaluate uterine anatomy (eg, flexion, fibroids). In settings where ultrasound is readily available, transabdominal ultrasound may be used instead of a pelvic examination to determine gestational age. Transvaginal ultrasound is also used if ectopic pregnancy or early pregnancy loss is suspected. (See  <a class="medical medical_review" href="/z/d/html/5487.html" rel="external">"Ectopic pregnancy: Clinical manifestations and diagnosis", section on 'Clinical presentation'</a> and  <a class="medical medical_review" href="/z/d/html/130879.html" rel="external">"Pregnancy loss (miscarriage): Ultrasound diagnosis"</a>.)</p><p class="headingAnchor" id="H4008464416"><span class="h2">Laboratory testing and alloimmunization prevention</span><span class="headingEndMark"> — </span>Confirmation of pregnancy typically requires a high-sensitivity urine pregnancy test or ultrasound. Laboratory testing for hemoglobin or hematocrit, chlamydia and/or gonorrhea, and recommendations for RhD testing and administration of <a class="drug drug_general" data-topicid="9858" href="/z/d/drug information/9858.html" rel="external">anti-D immune globulin</a> are described in detail separately. (See  <a class="medical medical_review" href="/z/d/html/3313.html" rel="external">"Overview of pregnancy termination", section on 'Laboratory testing'</a> and  <a class="medical medical_review" href="/z/d/html/3313.html" rel="external">"Overview of pregnancy termination", section on 'Alloimmunization prevention'</a>.)</p><p class="headingAnchor" id="H3436301000"><span class="h2">Antibiotic prophylaxis</span><span class="headingEndMark"> — </span>For patients undergoing first-trimester uterine aspiration abortion, we recommend antibiotic prophylaxis, consistent with guidelines from the Society of Family Planning (SFP), American College of Obstetricians and Gynecologists (ACOG), and Royal College of Obstetricians (RCOG) [<a href="#rid6">6,10,11</a>]. </p><p>Typical antibiotic regimens include  (<a class="graphic graphic_table graphicRef129043" href="/z/d/graphic/129043.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef87200" href="/z/d/graphic/87200.html" rel="external">table 2</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Preferred: <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">Doxycycline</a> (200 mg orally, one dose) one hour prior to the procedure [<a href="#rid10">10</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Alternatives:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">Metronidazole</a> (500 mg orally, one dose) one hour prior to the procedure. This is a commonly used regimen and is effective based on clinical experience but has not been well studied [<a href="#rid12">12</a>].</p><p></p><p class="bulletIndent2">or</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">Azithromycin</a> (500 mg orally, one dose) one hour prior to the procedure. This is a commonly used regimen and is effective based on clinical experience but has not been well studied [<a href="#rid12">12</a>]. We prefer 500 mg rather than 1000 mg because it causes less nausea.</p><p></p><p>While prophylactic antibiotics should ideally be given one hour prior to the procedure, they may be given up to 12 hours prior [<a href="#rid6">6</a>]. </p><p>Randomized trials and meta-analyses have demonstrated that prophylactic antibiotic therapy reduces the risk of genital tract infection after first-trimester uterine aspiration abortion [<a href="#rid13">13,14</a>]. In a meta-analysis of 21 randomized trials including patients undergoing first-trimester uterine aspiration, antibiotic prophylaxis compared with placebo or no antibiotics resulted in lower rates of genital tract infection (4.3 versus 6 percent, relative risk [RR] 0.72, 95% CI 0.58-0.90) [<a href="#rid14">14</a>]. </p><p>The choice of regimen is guided mostly by susceptibility patterns of likely pathogens, bioavailability of antimicrobials, and clinical experience [<a href="#rid6">6,10,11</a>]. Based on the available limited data, no single agent or regimen appears to be superior to others [<a href="#rid13">13,14</a>]. In the meta-analysis of placebo-controlled trials described above, the benefit of prophylactic antibiotics did not appear to differ according to the type of antibiotic or dosing regimen used [<a href="#rid14">14</a>]. The trials included in the meta-analysis used a wide range of antibiotic regimens; many investigated regimens with two or more antibiotics given in multiple doses, including regimens with both pre- and postoperative administration [<a href="#rid13">13,14</a>]. There have been few studies directly comparing one regimen versus another [<a href="#rid13">13</a>]. </p><p class="headingAnchor" id="H1214545809"><span class="h2">Thromboprophylaxis</span><span class="headingEndMark"> — </span>For most patients, thromboprophylaxis (either pharmacologic or mechanical) is not required as first-trimester uterine aspiration is a minor procedure with a low risk of venous thromboembolism; early ambulation is encouraged. This is in accordance with American College of Chest Physicians guidelines [<a href="#rid15">15</a>]. (See  <a class="medical medical_review" href="/z/d/html/1339.html" rel="external">"Prevention of venous thromboembolic disease in adult nonorthopedic surgical patients"</a>.)</p><p class="headingAnchor" id="H2903009743"><span class="h2">Limited role for cervical preparation</span><span class="headingEndMark"> — </span>Cervical preparation with osmotic dilators or medications (eg, <a class="drug drug_general" data-topicid="9657" href="/z/d/drug information/9657.html" rel="external">misoprostol</a>) is <strong>not</strong> routinely used for most patients undergoing first-trimester aspiration abortion; cervical preparation delays the procedure, is associated with risk of complications and side effects, and does not confer proven benefit.</p><p>However, there are some exceptions, and for patients in whom dilation may be more difficult or are at an increased risk of cervical injury, preprocedure cervical preparation may be appropriate. This is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/111284.html" rel="external">"Pregnancy termination: Cervical preparation for procedural abortion", section on '12 to &lt;14 weeks'</a>.)</p><p class="headingAnchor" id="H1532768092"><span class="h2">Procedure setting</span><span class="headingEndMark"> — </span>The vast majority (80 to 90 percent) of first-trimester uterine aspiration procedures in the United States can be performed safely in an outpatient clinical setting (eg, office, ambulatory surgery center) [<a href="#rid16">16,17</a>]. In a study including over 23,000 first-trimester aspiration abortion procedures from a United States private insurance database, those performed at ambulatory surgery centers compared with office-based settings had similarly low rates (2.2 and 2.6 percent) of adverse events [<a href="#rid18">18</a>]. </p><p>Hospital admission after uterine aspiration is rare and there are no absolute indications for hospital-based terminations. Rather, criteria for a hospital-based procedure depends on patient's history (eg, hemodynamic stability, severity of comorbidities), provider's experience level, resources at their clinic, and available resources for referral. Patients who need an abortion and who are unstable or those already hospitalized for acute illnesses or other medical conditions (eg, decompensated heart failure, severe symptomatic anemia) may be best managed as an inpatient. Some geographic areas have limited access to abortion care and hospital-based care may not be readily available. For patients with medical comorbidities in such areas, outpatient or ambulatory care centers with deep sedation or higher-level staffing (eg, anesthesiologist, certified nurse anesthetist) are appropriate alternatives.</p><p class="headingAnchor" id="H3483723767"><span class="h1">PAIN MANAGEMENT</span><span class="headingEndMark"> — </span>Pain associated with first-trimester uterine aspiration may be alleviated by a variety of analgesics as well as nonpharmacologic methods. Clinicians may find that an individualized analgesia plan to match patient preferences and expectations is most appropriate for their practice [<a href="#rid19">19</a>].</p><p class="headingAnchor" id="H3797315700"><span class="h2">Basic measures</span><span class="headingEndMark"> — </span>In many patients, pain is adequately controlled with nonsteroidal antiinflammatory drugs (NSAIDs), local anesthesia, and verbal support. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>NSAID</strong> – <a class="drug drug_general" data-topicid="8547" href="/z/d/drug information/8547.html" rel="external">Ibuprofen</a> is typically administered 30 to 60 minutes before the procedure [<a href="#rid20">20</a>]. </p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="8547" href="/z/d/drug information/8547.html" rel="external">Ibuprofen</a> is generally preferred over <a class="drug drug_general" data-topicid="8591" href="/z/d/drug information/8591.html" rel="external">ketorolac</a> as it is given orally and is equally effective [<a href="#rid21">21</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Paracervical block </strong>– Use of a paracervical block for local anesthesia is nearly universal in first-trimester uterine aspiration  (<a class="graphic graphic_figure graphicRef64237" href="/z/d/graphic/64237.html" rel="external">figure 1</a>) [<a href="#rid22">22</a>]. We use 20 mL of buffered 1% <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">lidocaine</a>; an alternative is 1% <a class="drug drug_general" data-topicid="9245" href="/z/d/drug information/9245.html" rel="external">chloroprocaine</a>. (See <a class="local">'Paracervical block'</a> below.)</p><p></p><p class="bulletIndent1">In one randomized trial including 120 patients undergoing first-trimester uterine aspiration, those receiving a paracervical block (20 mL of 1% buffered <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">lidocaine</a>) compared with a sham block had lower pain scores with cervical dilation and aspiration and higher satisfaction scores for pain control and the procedure overall [<a href="#rid23">23</a>]. A cervical block with lidocaine has also been described. In this randomized trial including 50 patients undergoing first-trimester uterine aspiration, those receiving a paracervical block with lidocaine combined with <a class="drug drug_general" data-topicid="8591" href="/z/d/drug information/8591.html" rel="external">ketorolac</a> compared with oral <a class="drug drug_general" data-topicid="8547" href="/z/d/drug information/8547.html" rel="external">ibuprofen</a> and a standard lidocaine block had improved pain after cervical dilation (60 versus 75 mm, on a scale of 0 to 100 mm), but not other procedure-related pain [<a href="#rid24">24</a>].</p><p></p><p class="bulletIndent1">The paracervical block technique and commonly used anesthetic agents are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/5404.html" rel="external">"Pudendal and paracervical block", section on 'Gynecologic procedures'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Verbal support</strong> – In the awake patient, a designated support person can provide verbal support and reassurance to decrease anxiety, which in turn may decrease pain. This method may include distractions through unrelated conversation or guided breathing and relaxation techniques. The support person may be a friend, partner, trained staff member, or doula who sits close to the patient during the procedure. Randomized trials and qualitative research point to positive outcomes from using abortion doula services, such as a reduced need for additional clinical support staff [<a href="#rid25">25-27</a>].</p><p></p><p class="bulletIndent1">The use of neutral or nonspecific language during procedures has also been shown in some but not all studies to reduce pain perception [<a href="#rid28">28-30</a>]. Some suggestions for neutral communication for abortion and gynecologic care are outlined in the table  (<a class="graphic graphic_table graphicRef113328" href="/z/d/graphic/113328.html" rel="external">table 3</a>). Also, giving the patient some control (eg, taking a break in the middle of the procedure, requesting additional medication) may also decrease anxiety.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other</strong> – We view use of an opioid analgesic as optional as it has no proven benefits. In one randomized trial including 120 patients undergoing first-trimester uterine aspiration, <a class="drug drug_general" data-topicid="91299" href="/z/d/drug information/91299.html" rel="external">hydrocodone</a>/<a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> compared with placebo increased postoperative nausea without other benefit [<a href="#rid31">31</a>].</p><p></p><p class="headingAnchor" id="H15201672"><span class="h2">Role of procedural sedation</span><span class="headingEndMark"> — </span>While many patients have adequate pain control with the above measures (see <a class="local">'Basic measures'</a> above), procedural sedation may be used, where available, to enhance pain control. Since most first-trimester abortions are performed in the outpatient setting, it is uncommon to administer moderate or deep sedation. Any patient taking oral or IV sedating medications should be instructed that they cannot drive themselves home after the procedure and must have a confirmed person to take them home afterwards. Requiring a driver, particularly for a procedure widely associated with social stigma and potential legal risk, may be a barrier for some patients and should be kept in mind when planning the use of oral or IV sedation.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>IV sedation</strong> – IV sedation must be administered by a licensed practitioner (eg, physician, certified nurse midwife, registered nurse), and all patients receiving moderate sedation or deeper must have cardiorespiratory monitoring by a clinician other than the provider performing the procedure. These issues are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/264.html" rel="external">"Procedural sedation in adults in the emergency department: General considerations, preparation, monitoring, and mitigating complications", section on 'Preparation and monitoring'</a>.)</p><p></p><p class="bulletIndent1">When IV sedation is chosen, we use <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">fentanyl</a> 100 mcg and <a class="drug drug_general" data-topicid="9650" href="/z/d/drug information/9650.html" rel="external">midazolam</a> 2 mg at the start of the procedure. Additional details of this combination and other options are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/139217.html" rel="external">"Procedural sedation in adults in the emergency department: Medication selection, dosing, and discharge criteria", section on 'Coadministration of midazolam and fentanyl'</a> and  <a class="medical medical_review" href="/z/d/html/139217.html" rel="external">"Procedural sedation in adults in the emergency department: Medication selection, dosing, and discharge criteria", section on 'Medication choice and dosing when increased risk of complications'</a>.)</p><p></p><p class="bulletIndent1">IV sedation provides enhanced pain control. In one randomized control trial of 130 patients, those receiving IV sedation (<a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">fentanyl</a> 100 mcg and <a class="drug drug_general" data-topicid="9650" href="/z/d/drug information/9650.html" rel="external">midazolam</a> 2 mg) compared with oral sedation (<a class="drug drug_general" data-topicid="9729" href="/z/d/drug information/9729.html" rel="external">oxycodone</a> 10 mg and <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">lorazepam</a> 1 mg sublingual), had lower adjusted intraoperative pain scores (36 versus 61 on verbal rating scale of 0 to 100) [<a href="#rid32">32</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Oral anxiolysis</strong> – As the higher level of staffing required for IV sedation is not available in all settings, many providers rely on oral anxiolytics to reduce preprocedural anxiety. </p><p></p><p class="bulletIndent1">When oral anxiolysis is chosen, we most commonly give <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">lorazepam</a> (0.5 to 2 mg sublingual) 30 minutes prior to the procedure. Some outpatient clinics may have the ability to directly dispense medications, while other providers may prescribe benzodiazepines in advance for patients to bring with them for administration in clinic prior to the procedure. </p><p></p><p class="bulletIndent1">In a randomized trial involving 124 patients undergoing first-trimester uterine aspiration, those receiving an oral anxiolytic (<a class="drug drug_general" data-topicid="9650" href="/z/d/drug information/9650.html" rel="external">midazolam</a>) prior to the procedure had less preprocedural anxiety compared with those who received placebo, though pain scores were similar in both groups [<a href="#rid33">33</a>]. Patients in the midazolam group had less nausea and more commonly reported partial amnesia; however, they were also more likely to have postoperative dizziness and sleepiness.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10086" href="/z/d/drug information/10086.html" rel="external">Nitrous oxide</a> – While nitrous oxide does not appear to be superior to oral or IV sedatives during uterine aspiration, its limited duration of side effects and lack of restriction on driving home afterwards may be advantageous in the outpatient setting for some patients. This is especially true for patients who need to drive long distances to access abortion services due to geographic or legal restrictions. </p><p></p><p class="bulletIndent1">In one randomized trial including 140 patients undergoing first-trimester uterine aspiration, use of <a class="drug drug_general" data-topicid="10086" href="/z/d/drug information/10086.html" rel="external">nitrous oxide</a> with oxygen (N<sub>2</sub>O/O<sub>2</sub>) compared with oral <a class="drug drug_general" data-topicid="91299" href="/z/d/drug information/91299.html" rel="external">hydrocodone</a>/<a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> and <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">lorazepam</a> resulted in similar pain scores and patient satisfaction [<a href="#rid34">34</a>]. However, in another randomized trial evaluating the use of nitrous oxide for pain control during hysteroscopic sterilization, N<sub>2</sub>O/O<sub>2</sub> compared with oral medications alone resulted in lower mean pain scores (22.8 versus 54.5 on 100 mm visual analog scale) [<a href="#rid35">35</a>]; the concentration of N<sub>2</sub>O/O<sub>2</sub> was titrated up to a maximum of 70:30 more frequently than in the uterine aspiration study.</p><p></p><p>Further information on patient selection and administration of procedural sedation can be found separately. (See  <a class="medical medical_review" href="/z/d/html/264.html" rel="external">"Procedural sedation in adults in the emergency department: General considerations, preparation, monitoring, and mitigating complications"</a> and  <a class="medical medical_review" href="/z/d/html/139217.html" rel="external">"Procedural sedation in adults in the emergency department: Medication selection, dosing, and discharge criteria"</a>.)</p><p class="headingAnchor" id="H2655632363"><span class="h1">PROCEDURE</span></p><p class="headingAnchor" id="H1674374236"><span class="h2">Patient positioning and procedural instruments</span><span class="headingEndMark"> — </span>The patient is guided into a recumbent position suitable for a pelvic examination. </p><p>As in other vaginal procedures, gloves are used, but a vaginal procedure cannot be sterile. Thus, sterile gloves are not required if the clinician utilizes a no-touch technique to maintain sterility of all instruments that pass through the cervical os. (See  <a class="medical medical_review" href="/z/d/html/3301.html" rel="external">"Overview of preoperative evaluation and preparation for gynecologic surgery", section on 'Vaginal preparation'</a>.)</p><p>The picture shows a typical equipment tray for manual uterine aspiration  (<a class="graphic graphic_picture graphicRef113329" href="/z/d/graphic/113329.html" rel="external">picture 1</a>).</p><p class="headingAnchor" id="H2334336184"><span class="h2">Paracervical block</span><span class="headingEndMark"> — </span>Following a bimanual pelvic examination to assess uterine size and flexion, a vaginal speculum is used to visualize the cervix. Antiseptic solution (eg, povidone-iodine, <a class="drug drug_general" data-topicid="9244" href="/z/d/drug information/9244.html" rel="external">chlorhexidine</a>) may be used to cleanse the cervix prior to uterine aspiration, though this practice has not been shown to prevent abortion-related infection [<a href="#rid6">6</a>].</p><p>Approximately 2 mL of local anesthetic (eg, 1% buffered <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">lidocaine</a>) is injected into the cervical stroma at the planned location of tenaculum placement. Use of a tenaculum with adequate traction will straighten the cervicouterine angle for safer passage of intrauterine instruments during dilation and aspiration. A paracervical block, typically using a total of 20 mL of local anesthetic, is then administered  (<a class="graphic graphic_figure graphicRef64237" href="/z/d/graphic/64237.html" rel="external">figure 1</a>). (See <a class="local">'Basic measures'</a> above.)</p><p class="headingAnchor" id="H78266071"><span class="h2">Mechanical dilation</span><span class="headingEndMark"> — </span>For most patients, mechanical cervical dilation is required to accommodate the cannula size that is necessary to remove the pregnancy tissue. Mechanical dilation may not be necessary for patients with gestations less than 7 0/7 weeks.</p><p>Cannulas are sized by diameter, and most clinicians choose a diameter equal to the number of weeks of gestation or 1 mm smaller. For example, at seven weeks, the tissue can be aspirated safely and effectively with a 7 mm or a 6 mm cannula. Sequential rigid dilators are passed until adequate dilation is reached to pass the desired cannula. If dilation cannot be achieved, additional cervical preparation may be warranted before proceeding with aspiration. (See  <a class="medical medical_review" href="/z/d/html/111284.html" rel="external">"Pregnancy termination: Cervical preparation for procedural abortion"</a>.)</p><p class="headingAnchor" id="H21913032"><span class="h2">Uterine evacuation</span></p><p class="headingAnchor" id="H39638780"><span class="h3">Aspiration procedure</span><span class="headingEndMark"> — </span>Aspiration is performed with a flexible or rigid, curved or straight plastic cannula attached to a manual or electric vacuum aspirator  (<a class="graphic graphic_figure graphicRef78988" href="/z/d/graphic/78988.html" rel="external">figure 2</a>). Sharp curettage alone (without aspiration) is not effective to accomplish uterine evacuation, and the World Health Organization strongly recommends <strong>against</strong> its routine use as a standalone abortion procedure in the first trimester [<a href="#rid36">36,37</a>].</p><p>Choice of cannula type is based on provider preference, as they can be used interchangeably with each type of aspirator. Some clinicians prefer to use a flexible, straight cannula with a manual uterine aspirator (MUA) for gestations ≤10 weeks and use a rigid, curved cannula with an electric vacuum aspirator (EVA) for gestations &gt;10 weeks. Extraction forceps may also be needed for later gestational ages (eg, &gt;15 0/7 weeks gestation). (See  <a class="medical medical_review" href="/z/d/html/104595.html" rel="external">"Second-trimester pregnancy termination: Dilation and evacuation", section on 'Uterine evacuation'</a>.)</p><p>For gestations ≤10 weeks, MUA and EVA have similar rates of successful uterine evacuation, patient acceptability, and major complications [<a href="#rid38">38,39</a>]. By contrast, for gestations ≤50 days, pooled analyses from randomized trials show that MUA had less blood loss and less perceived pain but a longer procedure time than EVA [<a href="#rid39">39</a>]. MUA is also quieter (which may make it preferable for some patients [<a href="#rid40">40,41</a>]), more portable, less expensive, and does not require electricity (which makes it favorable for use in resource-limited settings).</p><p>The completion of the procedure is signaled by a gritty sensation of the endometrium at the top of the cannula and the strength of the empty uterus contracting around the cannula.</p><p class="headingAnchor" id="H2907718540"><span class="h3">Role of ultrasound during procedure</span><span class="headingEndMark"> — </span>Ultrasound guidance during the aspiration procedure may be employed at the discretion of the provider, as there is no evidence for or against its practice in the first trimester. It is most often used if there is suspicion or knowledge of uterine abnormalities (eg, fibroids, bicornuate uterus), multiple gestation, difficult cervical dilation, procedures performed at later gestational ages (eg, ≥12 or 14 weeks), or when teaching uterine aspiration skills.</p><p class="headingAnchor" id="H317380233"><span class="h2">Tissue evaluation</span></p><p class="headingAnchor" id="H3128494184"><span class="h3">Expected findings</span><span class="headingEndMark"> — </span>After uterine aspiration, most clinicians examine the products of conception (POC).</p><p>POC findings that confirm a complete abortion vary by gestation  (<a class="graphic graphic_picture graphicRef141965" href="/z/d/graphic/141965.html" rel="external">picture 2</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>≤9 weeks of gestation – Identification of the appropriately sized gestational sac is sufficient to confirm completion of procedure.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>10 to &lt;12 weeks – In addition to the gestational sac, fetal parts may begin to be identified.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>≥12 weeks – Four extremities, spine, calvarium, gestational sac, and placenta must all be identified.</p><p></p><p class="headingAnchor" id="H1784996814"><span class="h3">Inadequate products of conception</span><span class="headingEndMark"> — </span>If inadequate POC are suspected at the time of the procedure, the first-line approach is to repeat aspiration immediately. When available, we use intraoperative transabdominal ultrasound guidance to guide re-aspiration and to assure the cannula is reaching the uterine fundus and pregnancy tissue. For retained POC easily identified on transabdominal ultrasound prior to re-aspiration, this intraoperative sonogram is often sufficient to confirm a successful evacuation. </p><p>When transabdominal ultrasound does not identify retained POC, transvaginal ultrasound may be performed. If POC are still not identified, a diagnosis of ectopic pregnancy, uterine anomaly (which may be complicating access to the pregnancy), or very early intrauterine gestation (for which tissue may not be easily identified) should be further considered. For such patients, serial laboratory testing of quantitative serum beta human chorionic gonadotropin (hCG) is often required. A serum level is drawn on the day of the aspiration as a baseline, and a repeat hCG is measured in 24 to 48 hours. A fall in hCG of at least 50 percent indicates the pregnancy was intrauterine and the aspiration procedure was successful [<a href="#rid37">37,42,43</a>]. If there is an inadequate decline or a rise in hCG levels, further evaluation (with ultrasound and/or hCG level) for retained POC, ongoing pregnancy, or ectopic pregnancy is needed. (See  <a class="medical medical_review" href="/z/d/html/134770.html" rel="external">"Approach to the patient with pregnancy of unknown location", section on 'Hemodynamically stable patients'</a> and  <a class="medical medical_review" href="/z/d/html/5487.html" rel="external">"Ectopic pregnancy: Clinical manifestations and diagnosis", section on 'Diagnostic evaluation'</a> and <a class="local">'Incomplete or failed abortion'</a> below.)</p><p class="headingAnchor" id="H3012563493"><span class="h1">RECOVERY AND FOLLOW-UP</span><span class="headingEndMark"> — </span>Postprocedure recovery time is typically 20 to 30 minutes for patients who receive minimal or moderate sedation. During recovery, the patient should be assessed for stable vital signs, vaginal bleeding, adequate pain control, and ability to ambulate independently at time of discharge. Postprocedure care and instructions are provided in writing and reviewed verbally  (<a class="graphic graphic_table graphicRef126344" href="/z/d/graphic/126344.html" rel="external">table 4</a>).</p><p>While data do not support routine postprocedure visits after uterine aspiration [<a href="#rid44">44</a>], warning signs that indicate need for a postprocedure visit include [<a href="#rid45">45</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Vaginal bleeding more than two maxi pads per hour for more than two consecutive hours</p><p class="bulletIndent1"><span class="glyph">●</span>Cramps that are persistent and worsening despite pain medication</p><p class="bulletIndent1"><span class="glyph">●</span>Temperature ≥100.4°F (38°C)</p><p></p><p>We inform all patients about their ability to get pregnant quickly following pregnancy termination and that contraceptive methods can be placed, dispensed, or prescribed on procedure day, if desired [<a href="#rid46">46</a>]. (See  <a class="medical medical_review" href="/z/d/html/109209.html" rel="external">"Contraception: Postabortion", section on 'Initiation of contraception'</a> and  <a class="medical medical_review" href="/z/d/html/3313.html" rel="external">"Overview of pregnancy termination", section on 'Plan for contraception'</a>.)</p><p class="headingAnchor" id="H4291371502"><span class="h1">COMPLICATIONS</span><span class="headingEndMark"> — </span>First-trimester uterine aspiration is a safe and effective procedure for appropriately selected patients [<a href="#rid47">47</a>]; the overall complication rate is approximately 9 per 1000 [<a href="#rid48">48</a>]. Major complications (suspected perforation, missed ectopic pregnancy, hemorrhage, sepsis) are rare (0.71 per 1000) [<a href="#rid49">49</a>]. </p><p class="headingAnchor" id="H111413571"><span class="h2">Maternal mortality</span><span class="headingEndMark"> — </span>The overall death rate from all legal abortions is far less than the maternal mortality ratio among patients with term pregnancies in the United States. (See  <a class="medical medical_review" href="/z/d/html/3313.html" rel="external">"Overview of pregnancy termination", section on 'Maternal mortality'</a>.)</p><p>In a systematic review including 57 studies evaluating complications after first-trimester aspiration abortion, no abortion-related deaths were reported (six studies, over 220,000 patients) [<a href="#rid50">50</a>]. One additional study in this review including over 20,000 patients reported four maternal deaths, but none were attributed to complications from the procedure (deaths were from external causes, such as suicide and homicide) [<a href="#rid51">51</a>]. </p><p class="headingAnchor" id="H554351794"><span class="h2">Infection</span><span class="headingEndMark"> — </span>Postabortal endometritis is uncommon when antibiotic prophylaxis is used (see <a class="local">'Antibiotic prophylaxis'</a> above). In a 2015 systematic review including five office-based studies in which all patients received antibiotic prophylaxis prior to first-trimester uterine aspiration, &lt;2 percent of patients required outpatient treatment for presumed or diagnosed infection [<a href="#rid50">50</a>].</p><p>Management of patients with postabortal endometritis is as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with suspected postabortion infection who are hemodynamically stable and are not toxic-appearing can be treated with oral antibiotics as an outpatient. We prescribe broad-spectrum antibiotic therapy (with coverage of anaerobes) such as: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">Ceftriaxone</a> 500 mg intramuscularly once <strong>plus</strong> </p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">Doxycycline</a> 100 mg orally twice daily for 14 days <strong>plus</strong> </p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">Metronidazole</a> 500 mg orally twice daily for 14 days </p><p></p><p class="bulletIndent1">This regimen is in accordance with Centers for Disease Control and Prevention guidelines for pelvic inflammatory disease [<a href="#rid52">52</a>]. (See  <a class="medical medical_review" href="/z/d/html/7585.html" rel="external">"Pelvic inflammatory disease: Treatment in adults and adolescents", section on 'Outpatient therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients in whom more severe infection or sepsis is suspected (eg, generalized abdominal tenderness, guarding, tachycardia, high fever, lethargy), or those who fail outpatient management, require aggressive therapy with broad spectrum intravenous antibiotics, assessment for uterine perforation, and inpatient monitoring and support, possibly in an intensive care unit. (See  <a class="medical medical_review" href="/z/d/html/130878.html" rel="external">"Septic abortion: Clinical presentation and management", section on 'Management'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Any retained products of conception (POC) or blood clot found on ultrasound in the setting of suspected infection should be evacuated. (See <a class="local">'Incomplete or failed abortion'</a> below.)</p><p></p><p class="headingAnchor" id="H2706904308"><span class="h2">Hemorrhage</span><span class="headingEndMark"> — </span>Postabortal hemorrhage (eg, bleeding requiring transfusion or admission, bleeding &gt;500 mL) is uncommon with first-trimester uterine aspiration. In the systematic review discussed above (see <a class="local">'Maternal mortality'</a> above), hemorrhage requiring transfusion occurred in ≤0.1 percent of procedures [<a href="#rid50">50</a>]. </p><p>When hemorrhage does occur, it usually results from uterine atony, cervical or vaginal lacerations, uterine perforation, or retained tissue. Abnormal placentation (usually a result of prior cesarean birth, endometrial ablation, or other uterine surgery in which there was damage to the endometrial-myometrial interface) may also result in significant bleeding with uterine aspiration but is rare in early gestations. </p><p>If abnormal placentation is suspected prior to the procedure, additional precautions (eg, use of intraoperative ultrasound, avoiding direct suction curettage over the uterine scar or area of suspected abnormal implantation, having an electric vacuum aspirator immediately available, advanced notification of back-up providers such as a gynecologic surgeon or interventional radiologist) should be taken. Depending on availability and access, providers may consider using an operating room with blood products available. </p><p>Our management approach of such patients is like that of The Society of Family Planning (SFP) guidelines and is discussed in detail separately [<a href="#rid53">53</a>]. (See  <a class="medical medical_review" href="/z/d/html/3313.html" rel="external">"Overview of pregnancy termination", section on 'Hemorrhage'</a>.)</p><p class="headingAnchor" id="H1070238465"><span class="h2">Cervical or vaginal laceration</span><span class="headingEndMark"> — </span>Cervical or vaginal trauma from first-trimester uterine aspiration is rare (≤0.1 percent) [<a href="#rid50">50</a>], but risk can be reduced by appropriate cervical preparation in patients in whom difficult mechanical dilation is anticipated. (See <a class="local">'Limited role for cervical preparation'</a> above.)</p><p>Most cervical or vaginal trauma during first-trimester uterine aspiration can be controlled with direct pressure for one to two minutes. For cervical lacerations, application of <a class="drug drug_general" data-topicid="9888" href="/z/d/drug information/9888.html" rel="external">silver nitrate</a> or <a class="drug drug_general" data-topicid="83319" href="/z/d/drug information/83319.html" rel="external">ferric subsulfate</a> (Monsel solution) may be useful. Lacerations that have persistent bleeding are repaired surgically with absorbable sutures; only a single suture is typically needed.</p><p class="headingAnchor" id="H4263541375"><span class="h2">Uterine perforation</span><span class="headingEndMark"> — </span>For both first- and second-trimester surgical termination procedures, the reported rate of uterine perforation is less than 0.6 percent [<a href="#rid50">50,54-56</a>]. In the systematic review discussed above (see <a class="local">'Maternal mortality'</a> above), uterine perforation in which additional interventions were necessary occurred in ≤0.1 to 2.3 percent of procedures (seven studies) [<a href="#rid50">50</a>]. </p><p>When uterine perforation is suspected, the aspiration procedure should be stopped to evaluate the extent of the perforation using ultrasound guidance. If there is no evidence of vascular or visceral injury (eg, excessive bleeding, hypotension, acute onset of hematuria) and the procedure is not complete, the procedure can continue under ultrasound guidance if the remaining pregnancy tissue can be safely reached. Less commonly, the procedure can be postponed for one to two weeks to allow closure of the perforation; the subsequent aspiration is performed under ultrasound guidance. By contrast, immediate surgical intervention is indicated if there are signs of severe uterine bleeding, or vascular or visceral injury are suspected. (See  <a class="medical medical_review" href="/z/d/html/3309.html" rel="external">"Uterine perforation during gynecologic procedures", section on 'Management'</a>.)</p><p>Post-procedure, the patient is typically monitored in the recovery room for one to two hours for signs of intraperitoneal hemorrhage or visceral injury. While some experts prescribe antibiotics (<a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> 500 mg by mouth twice daily for one week) for patients with suspected uterine perforation, other experts only administer antibiotics to those with clinical signs of infection (eg, endometritis, peritonitis). This is discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/3309.html" rel="external">"Uterine perforation during gynecologic procedures", section on 'Postprocedure monitoring'</a> and  <a class="medical medical_review" href="/z/d/html/3309.html" rel="external">"Uterine perforation during gynecologic procedures", section on 'Management'</a>.)</p><p class="headingAnchor" id="H1150947499"><span class="h2">Hematometra</span><span class="headingEndMark"> — </span>Immediate postoperative pain (eg, dull, aching lower abdominal pain) without overt bleeding from the vagina may indicate development of hematometra. Pain due to hematometra can sometimes be accompanied by tachycardia, diaphoresis, or nausea. The onset is usually within the first hour after completion of the procedure.</p><p>On pelvic examination, the uterus is often large, midline, globular and is tense and tender to palpation. Ultrasound examination may reveal an enlarged uterine cavity filled with echogenic material. Treatment requires immediate uterine evacuation, permitting the uterus to contract to a normal postprocedure size. Intramuscular <a class="drug drug_general" data-topicid="9637" href="/z/d/drug information/9637.html" rel="external">methylergonovine</a> maleate (0.2 mg) may be given to ensure continued contraction of the uterus [<a href="#rid57">57</a>].</p><p class="headingAnchor" id="H2724002845"><span class="h2">Incomplete or failed abortion</span><span class="headingEndMark"> — </span>All patients will continue to have an elevated level of hCG for a short period following pregnancy termination; a positive urine pregnancy test after an abortion is not diagnostic of ongoing pregnancy. Return of the serum hCG concentration to undetectable following pregnancy termination varies widely from 7 to 60 days [<a href="#rid42">42</a>], and depends primarily on the hCG concentration at the time of termination.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Incomplete abortion</strong> – Incomplete abortion refers to retained POC (ie, placental tissue, fetal fragments, fetal membranes) and is an uncommon complication of first-trimester uterine aspiration. In one series evaluating patients undergoing pregnancy termination and in whom follow-up information was available (80 percent of patients), retained POC were present in 4 of 672 first-trimester procedures [<a href="#rid58">58</a>].</p><p></p><p class="bulletIndent1">While presentation of retained POC can be similar to that of hematometra or endometritis (lower abdominal or pelvic pain and an enlarged or tender uterus), these entities can often be distinguished by the character and timing of these symptoms. For example, a patient with retained POC typically presents with pain and/or heavy or persistent vaginal bleeding days or weeks after the procedure. By contrast, hematometra is more likely to present with pain immediately postabortion (within one hour) and without heavy vaginal bleeding; endometritis is more likely to be accompanied by fever and pain that is not associated with sonographic evidence of retained tissue in the uterine cavity [<a href="#rid59">59</a>].</p><p></p><p class="bulletIndent1">Symptomatic patients with suspected retained POC are typically managed with repeat aspiration (to completely empty the uterus). <a class="drug drug_general" data-topicid="9657" href="/z/d/drug information/9657.html" rel="external">Misoprostol</a> is also an acceptable alternative, and expectant management can be offered to selected patients. By contrast, asymptomatic patients can often be managed expectantly. This is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/5482.html" rel="external">"Retained products of conception in the first half of pregnancy", section on 'Management'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Failed abortion </strong>– Failed abortion, or an ongoing pregnancy after an attempted pregnancy termination, is rare, but occurs more frequently at early gestational ages (eg, &lt;7 0/7 weeks of gestation when a definitive intrauterine pregnancy may not be seen on ultrasound) [<a href="#rid60">60-62</a>]. Ongoing pregnancy may also rarely result from a multiple gestation in which only one of the sacs was evacuated, or in those with uterine pathology (eg, congenital uterine anomaly, large submucosal fibroid) [<a href="#rid62">62,63</a>]. </p><p></p><p class="bulletIndent1">In a prospective study of 1132 uterine aspiration procedures up to seven weeks of gestation, the failed abortion rate was 15 per 1000; all providers inspected tissue on-site using flotation and backlighting, as is standard practice [<a href="#rid64">64</a>]. A modest reduction in failed abortion (rate of 1.3 per 1000) at &lt;7 weeks was seen in one case series of 2399 patients, in which a resource-intensive protocol included pre- and postabortion transvaginal ultrasonography, a rigid 7 mm cannula for aspiration, and colposcopic magnification for POC examination when needed to confirm procedure completion [<a href="#rid65">65,66</a>].</p><p></p><p class="bulletIndent1">The type and risk of possible damage to the ongoing pregnancy from an attempted abortion cannot be quantified and direct or indirect injury to the developing embryo could occur. </p><p></p><p class="headingAnchor" id="H4250210314"><span class="h1">SPECIAL CONSIDERATIONS</span></p><p class="headingAnchor" id="H1565994571"><span class="h2">Multiple gestations</span><span class="headingEndMark"> — </span>Uterine aspiration of multiple gestations in the first trimester can generally be approached like a single gestation of the same duration. For example, a six-week twin pregnancy can be successfully evacuated by manual uterine aspiration through a 6 mm cannula following the same steps as for a six-week singleton pregnancy.</p><p>An electric vacuum aspirator (EVA) rather than a manual uterine aspirator (MUA) may better accommodate the increased volume of tissue with multiple gestations, and uterotonics can treat excessive bleeding due to uterine atony. Many providers will also use ultrasound guidance for multiple gestations at an earlier gestational age than for singletons for reassurance of procedure completion as it may be difficult to assess from tissue examination if all gestational products were evacuated. (See <a class="local">'Expected findings'</a> above.)</p><p class="headingAnchor" id="H1494915057"><span class="h2">Uterine anomalies and abnormalities</span><span class="headingEndMark"> — </span>Uterine anomalies or abnormalities (eg, congenital uterine anomaly, large fibroids) can pose challenges in uterine aspiration. Ultrasound guidance is extremely helpful in navigating a divided or distorted endometrial cavity. Aspiration of the nonpregnant horn of a didelphic uterus is not necessary, but, if easily accomplished, may decrease postprocedure uterine bleeding.</p><p>Adjunctive use of <a class="drug drug_general" data-topicid="9657" href="/z/d/drug information/9657.html" rel="external">misoprostol</a> for cervical preparation may be useful for gestations &lt;12 weeks when cervical dilation is impaired by fibroids (see <a class="local">'Limited role for cervical preparation'</a> above). When large fibroids impede placement of the cannula at the fundus to reach the pregnancy, alternate instruments, such as EVA nozzle extenders may be helpful. Some providers anecdotally report modifying flexible cannulas in tandem or inserting a moldable metal uterine sound inside a cannula to navigate placement past fibroids.</p><p>Finally, it is important to remember that when uterine aspiration is not successful due to these anatomic challenges, medication abortion is often an alternative.</p><p class="headingAnchor" id="H3560419154"><span class="h2">Suspected molar pregnancy</span><span class="headingEndMark"> — </span>Molar pregnancy should be considered in any patient with a prior history of hydatidiform mole. Molar pregnancy may also be suspected preprocedure from characteristic ultrasound findings (eg, classic "snowstorm or Swiss cheese pattern" of a central heterogeneous mass in the uterus with numerous discrete anechoic spaces) or a markedly high serum hCG level. Postprocedure, a molar pregnancy may be suspected if hydropic swellings of the chorionic villi are seen during tissue examination.</p><p>In the case of suspected molar pregnancy, tissue should be sent for pathology evaluation. In our practice, we also send a serum hCG on the day of uterine evacuation as a baseline in case further monitoring is required. In the event of a confirmed molar diagnosis, protocols for hCG monitoring should be followed. (See  <a class="medical medical_review" href="/z/d/html/3194.html" rel="external">"Hydatidiform mole: Treatment and follow-up"</a>.)</p><p class="headingAnchor" id="H2046090829"><span class="h2">Future pregnancies</span><span class="headingEndMark"> — </span>Study results vary regarding uterine aspiration and risks to subsequent pregnancy. This is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3313.html" rel="external">"Overview of pregnancy termination", section on 'Future pregnancies'</a>.)</p><p class="headingAnchor" id="H3293855831"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/109182.html" rel="external">"Society guideline links: Pregnancy termination"</a>.)</p><p><strong>INFORMATION FOR PATIENTS</strong> — UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/15750.html" rel="external">"Patient education: Abortion (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/z/d/html/8400.html" rel="external">"Patient education: Abortion (pregnancy termination) (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H857239207"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical significance</strong> – Termination of pregnancy by uterine aspiration is a commonly used abortion method; most of these are done in the first trimester. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Counseling</strong> – Aspiration abortion and medication abortion are both safe and effective procedures for appropriately selected patients. The choice between the two methods is discussed elsewhere. (See <a class="local">'Patient selection'</a> above and  <a class="medical medical_review" href="/z/d/html/3313.html" rel="external">"Overview of pregnancy termination", section on 'Choice of procedure'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preprocedure evaluation</strong> <strong>and preparation</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Role of ultrasound</strong> – Ultrasound is useful if uterine size on examination is inconsistent with expected gestational age or if there is a suspicion of an ectopic pregnancy. (See <a class="local">'Physical examination and ultrasound'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Laboratories </strong>– Laboratory testing for hemoglobin or hematocrit, chlamydia and/or gonorrhea, as well as recommendations for RhD testing and administration of <a class="drug drug_general" data-topicid="9858" href="/z/d/drug information/9858.html" rel="external">anti-D immune globulin</a> are discussed in detail separately. (See <a class="local">'Laboratory testing and alloimmunization prevention'</a> above and  <a class="medical medical_review" href="/z/d/html/3313.html" rel="external">"Overview of pregnancy termination", section on 'Laboratory testing'</a> and  <a class="medical medical_review" href="/z/d/html/3313.html" rel="external">"Overview of pregnancy termination", section on 'Alloimmunization prevention'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Prophylactic antibiotics</strong> – For all patients undergoing first-trimester uterine aspiration abortion, we recommend antibiotic prophylaxis (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). Antibiotic prophylaxis reduces the risk of postabortion infection. We suggest <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> (single dose of 200 mg given orally one hour prior to the procedure) rather than other agents (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). However, alternative regimens are also reasonable, as summarized in the table  (<a class="graphic graphic_table graphicRef129043" href="/z/d/graphic/129043.html" rel="external">table 1</a>). (See <a class="local">'Antibiotic prophylaxis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Role of cervical preparation</strong> – Cervical preparation with osmotic dilators or cervical ripening medications is typically <strong>not</strong> required in first-trimester aspiration abortion. Exceptions to this are patients in whom difficult mechanical dilation is anticipated or if there is an increased risk of cervical injury. Guidance on the use of cervical preparation is provided separately. (See <a class="local">'Limited role for cervical preparation'</a> above and  <a class="medical medical_review" href="/z/d/html/111284.html" rel="external">"Pregnancy termination: Cervical preparation for procedural abortion", section on '12 to &lt;14 weeks'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pain management</strong> – Pain control for first-trimester aspiration abortion includes nonsteroidal antiinflammatory drugs (NSAIDs), local anesthesia with a paracervical block  (<a class="graphic graphic_figure graphicRef64237" href="/z/d/graphic/64237.html" rel="external">figure 1</a>), and verbal support. While procedural sedation (where available) may enhance pain control, a driver home is required which may be a barrier for some patients. (See <a class="local">'Pain management'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Procedure</strong> – The aspiration procedure includes a paracervical block, mechanical cervical dilation, and aspiration of uterine contents with a manual or electric aspirator  (<a class="graphic graphic_figure graphicRef78988" href="/z/d/graphic/78988.html" rel="external">figure 2</a>). Some suggestions for neutral communication for abortion and gynecologic care are outlined in the table  (<a class="graphic graphic_table graphicRef113328" href="/z/d/graphic/113328.html" rel="external">table 3</a>). After aspiration, the products of conception are examined to confirm complete uterine evacuation  (<a class="graphic graphic_picture graphicRef141965" href="/z/d/graphic/141965.html" rel="external">picture 2</a>). (See <a class="local">'Procedure'</a> above and <a class="local">'Tissue evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Recovery and follow-up</strong> – Future pregnancy plans may be discussed, and appropriate guidance given for preconception or contraceptive care. Patients should be counseled to seek medical attention if they have postprocedure symptoms, including excessive vaginal bleeding, persistent pelvic cramps, or temperature ≥100.4°F or 38°C  (<a class="graphic graphic_table graphicRef126344" href="/z/d/graphic/126344.html" rel="external">table 4</a>). (See <a class="local">'Recovery and follow-up'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Complications</strong> – First-trimester aspiration abortion is a safe procedure and major complications (eg, uterine perforation, hemorrhage, sepsis) are rare. (See <a class="local">'Complications'</a> above.)</p><p></p><p class="headingAnchor" id="H1064296815"><span class="h1">ACKNOWLEDGMENTS</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Frank W Ling, MD, and Lee P Shulman, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Dzuba IG, Chong E, Hannum C, et al. A non-inferiority study of outpatient mifepristone-misoprostol medical abortion at 64-70 days and 71-77 days of gestation. Contraception 2020; 101:302.</a></li><li class="breakAll">National Abortion Federation (NAF). Evidence-based guidelines that set the standards for abortion care in North America. https://prochoice.org/education-and-advocacy/cpg/ (Accessed on June 29, 2020).</li><li class="breakAll">World Health Organization. Abortion Care Guideline (2022). https://apps.who.int/iris/bitstream/handle/10665/349316/9789240039483-eng.pdf?sequence=1&amp;isAllowed=y (Accessed on November 10, 2022).</li><li class="breakAll">2022 Clinical Policy Guidelines for Abortion Care. National Abortion Federation. Available at: https://prochoice.org/providers/quality-standards/ (Accessed on October 30, 2023).</li><li class="breakAll">After Roe Fell: Abortion Laws by State. Center for Reproductive Rights. Available at: https://reproductiverights.org/maps/abortion-laws-by-state/ (Accessed on November 15, 2022).</li><li><a class="nounderline abstract_t">Achilles SL, Reeves MF, Society of Family Planning. Prevention of infection after induced abortion: release date October 2010: SFP guideline 20102. Contraception 2011; 83:295.</a></li><li><a class="nounderline abstract_t">Penney GC, Thomson M, Norman J, et al. A randomised comparison of strategies for reducing infective complications of induced abortion. Br J Obstet Gynaecol 1998; 105:599.</a></li><li><a class="nounderline abstract_t">Cameron ST, Sutherland S. Universal prophylaxis compared with screen-and-treat for Chlamydia trachomatis prior to termination of pregnancy. BJOG 2002; 109:606.</a></li><li class="breakAll">United States Preventive Services Task Force. Final recommendation statement: Chlamydia and gonorrhea: Screening. https://www.uspreventiveservicestaskforce.org/Page/Document/RecommendationStatementFinal/chlamydia-and-gonorrhea-screening (Accessed on August 02, 2017).</li><li><a class="nounderline abstract_t">ACOG Practice Bulletin No. 195: Prevention of Infection After Gynecologic Procedures. Obstet Gynecol 2018; 131:e172. Reaffirmed 2022.</a></li><li class="breakAll">Best practice in comprehensive abortion care, Royal College of Obstetricians and Gynaecologists, London 2015. https://www.rcog.org.uk/globalassets/documents/guidelines/best-practice-papers/best-practice-paper-2.pdf (Accessed on September 21, 2018).</li><li class="breakAll">Manual of medical standards and guidelines, Planned Parenthood Federation of America, Washington, DC 2016.</li><li><a class="nounderline abstract_t">Low N, Mueller M, Van Vliet HA, Kapp N. Perioperative antibiotics to prevent infection after first-trimester abortion. Cochrane Database Syst Rev 2012; 2012:CD005217.</a></li><li><a class="nounderline abstract_t">Islam N, Furuya-Kanamori L, Mahmood S, Thalib L. Prophylactic antibiotics for preventing genital tract infection in women undergoing surgical procedures for incomplete abortion: a systematic review and meta-analysis of randomised controlled trials. BJOG 2021; 128:1273.</a></li><li><a class="nounderline abstract_t">Guyatt GH, Akl EA, Crowther M, et al. Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:7S.</a></li><li><a class="nounderline abstract_t">Dalton VK, Harris L, Weisman CS, et al. Patient preferences, satisfaction, and resource use in office evacuation of early pregnancy failure. Obstet Gynecol 2006; 108:103.</a></li><li class="breakAll">Agency for Healthcare Research and Quality. Ambulatory surgery in U.S. hospitals, 2003. https://archive.ahrq.gov/data/hcup/factbk9/factbk9.pdf (Accessed on December 14, 2016).</li><li><a class="nounderline abstract_t">Roberts SCM, Upadhyay UD, Liu G, et al. Association of Facility Type With Procedural-Related Morbidities and Adverse Events Among Patients Undergoing Induced Abortions. JAMA 2018; 319:2497.</a></li><li><a class="nounderline abstract_t">Allen RH, Fortin J, Bartz D, et al. Women's preferences for pain control during first-trimester surgical abortion: a qualitative study. Contraception 2012; 85:413.</a></li><li><a class="nounderline abstract_t">Wiebe ER, Rawling M. Pain control in abortion. Int J Gynaecol Obstet 1995; 50:41.</a></li><li><a class="nounderline abstract_t">Braaten KP, Hurwitz S, Fortin J, Goldberg AB. Intramuscular ketorolac versus oral ibuprofen for pain relief in first-trimester surgical abortion: a randomized clinical trial. Contraception 2014; 89:116.</a></li><li><a class="nounderline abstract_t">O'Connell K, Jones HE, Simon M, et al. First-trimester surgical abortion practices: a survey of National Abortion Federation members. Contraception 2009; 79:385.</a></li><li><a class="nounderline abstract_t">Renner RM, Nichols MD, Jensen JT, et al. Paracervical block for pain control in first-trimester surgical abortion: a randomized controlled trial. Obstet Gynecol 2012; 119:1030.</a></li><li><a class="nounderline abstract_t">Cansino C, Edelman A, Burke A, Jamshidi R. Paracervical block with combined ketorolac and lidocaine in first-trimester surgical abortion: a randomized controlled trial. Obstet Gynecol 2009; 114:1220.</a></li><li><a class="nounderline abstract_t">Chor J, Hill B, Martins S, et al. Doula support during first-trimester surgical abortion: a randomized controlled trial. Am J Obstet Gynecol 2015; 212:45.e1.</a></li><li><a class="nounderline abstract_t">Wilson SF, Gurney EP, Sammel MD, Schreiber CA. Doulas for surgical management of miscarriage and abortion: a randomized controlled trial. Am J Obstet Gynecol 2017; 216:44.e1.</a></li><li><a class="nounderline abstract_t">Chor J, Lyman P, Tusken M, et al. Women's experiences with doula support during first-trimester surgical abortion: a qualitative study. Contraception 2016; 93:244.</a></li><li><a class="nounderline abstract_t">Dalton M, Dangel A, Strohsnitter W, Baecher-Lind L. The impact of gentle language on pain perception during colposcopy: a randomized controlled trial. J Low Genit Tract Dis 2014; 18:314.</a></li><li><a class="nounderline abstract_t">Ott J, Aust S, Nouri K, Promberger R. An everyday phrase may harm your patients: the influence of negative words on pain during venous blood sampling. Clin J Pain 2012; 28:324.</a></li><li><a class="nounderline abstract_t">Varelmann D, Pancaro C, Cappiello EC, Camann WR. Nocebo-induced hyperalgesia during local anesthetic injection. Anesth Analg 2010; 110:868.</a></li><li><a class="nounderline abstract_t">Micks EA, Edelman AB, Renner RM, et al. Hydrocodone-acetaminophen for pain control in first-trimester surgical abortion: a randomized controlled trial. Obstet Gynecol 2012; 120:1060.</a></li><li><a class="nounderline abstract_t">Allen RH, Fitzmaurice G, Lifford KL, et al. Oral compared with intravenous sedation for first-trimester surgical abortion: a randomized controlled trial. Obstet Gynecol 2009; 113:276.</a></li><li><a class="nounderline abstract_t">Bayer LL, Edelman AB, Fu R, et al. An Evaluation of Oral Midazolam for Anxiety and Pain in First-Trimester Surgical Abortion: A Randomized Controlled Trial. Obstet Gynecol 2015; 126:37.</a></li><li><a class="nounderline abstract_t">Singh RH, Montoya M, Espey E, Leeman L. Nitrous oxide versus oral sedation for pain management of first-trimester surgical abortion - a randomized study. Contraception 2017; 96:118.</a></li><li><a class="nounderline abstract_t">Schneider EN, Riley R, Espey E, et al. Nitrous oxide for pain management during in-office hysteroscopic sterilization: a randomized controlled trial. Contraception 2017; 95:239.</a></li><li class="breakAll">World Health Organization. Safe abortion: Technical and policy guidance for health systems, 2nd ed, Geneva 2012. http://www.who.int/reproductivehealth/publications/unsafe_abortion/9789241548434/en/ (Accessed on December 14, 2016).</li><li class="breakAll">National Abortion Federation. 2017 clinical policy guidelines. https://prochoice.org/resources/clinical-policy-guidelines/ (Accessed on August 02, 2017).</li><li><a class="nounderline abstract_t">Goldberg AB, Dean G, Kang MS, et al. Manual versus electric vacuum aspiration for early first-trimester abortion: a controlled study of complication rates. Obstet Gynecol 2004; 103:101.</a></li><li><a class="nounderline abstract_t">Wen J, Cai QY, Deng F, Li YP. Manual versus electric vacuum aspiration for first-trimester abortion: a systematic review. BJOG 2008; 115:5.</a></li><li><a class="nounderline abstract_t">Bird ST, Harvey SM, Beckman LJ, et al. Similarities in women's perceptions and acceptability of manual vacuum aspiration and electric vacuum aspiration for first trimester abortion. Contraception 2003; 67:207.</a></li><li><a class="nounderline abstract_t">Dean G, Cardenas L, Darney P, Goldberg A. Acceptability of manual versus electric aspiration for first trimester abortion: a randomized trial. Contraception 2003; 67:201.</a></li><li><a class="nounderline abstract_t">Steier JA, Bergsjø P, Myking OL. Human chorionic gonadotropin in maternal plasma after induced abortion, spontaneous abortion, and removed ectopic pregnancy. Obstet Gynecol 1984; 64:391.</a></li><li><a class="nounderline abstract_t">Midgley AR Jr, Jaffe RB. Regulation of human gonadotropins. II. Disappearance of human chorionic gonadotropin following delivery. J Clin Endocrinol Metab 1968; 28:1712.</a></li><li><a class="nounderline abstract_t">Grossman D, Ellertson C, Grimes DA, Walker D. Routine follow-up visits after first-trimester induced abortion. Obstet Gynecol 2004; 103:738.</a></li><li class="breakAll">Training in Early Abortion for Comprehensive Healthcare (TEACH). Early abortion training workbook. http://www.teachtraining.org/trainingworkbook/EarlyAbortionTrainingWorkbook2012.pdf (Accessed on December 14, 2016).</li><li><a class="nounderline abstract_t">Bellanca HK, Hunter MS. ONE KEY QUESTION®: Preventive reproductive health is part of high quality primary care. Contraception 2013; 88:3.</a></li><li><a class="nounderline abstract_t">ACOG. ACOG practice bulletin. Clinical management guidelines of obstetrician-gynecologists. Number 67, October 2005. Medical management of abortion. Obstet Gynecol 2005; 106:871.</a></li><li><a class="nounderline abstract_t">Hakim-Elahi E, Tovell HM, Burnhill MS. Complications of first-trimester abortion: a report of 170,000 cases. Obstet Gynecol 1990; 76:129.</a></li><li class="breakAll">Management of Unintended and Abnormal Pregnancy: Comprehensive Abortion Care, Paul M, Lichtenberg E, Borgatta L, et al (Eds), Blackwell Publishing Ltd, West Sussex, United Kingdom 2009.</li><li><a class="nounderline abstract_t">White K, Carroll E, Grossman D. Complications from first-trimester aspiration abortion: a systematic review of the literature. Contraception 2015; 92:422.</a></li><li><a class="nounderline abstract_t">Niinimäki M, Pouta A, Bloigu A, et al. Immediate complications after medical compared with surgical termination of pregnancy. Obstet Gynecol 2009; 114:795.</a></li><li><a class="nounderline abstract_t">Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep 2021; 70:1.</a></li><li><a class="nounderline abstract_t">Kerns J, Steinauer J. Management of postabortion hemorrhage: release date November 2012 SFP Guideline #20131. Contraception 2013; 87:331.</a></li><li><a class="nounderline abstract_t">Grossman D, Blanchard K, Blumenthal P. Complications after second trimester surgical and medical abortion. Reprod Health Matters 2008; 16:173.</a></li><li><a class="nounderline abstract_t">Amarin ZO, Badria LF. A survey of uterine perforation following dilatation and curettage or evacuation of retained products of conception. Arch Gynecol Obstet 2005; 271:203.</a></li><li><a class="nounderline abstract_t">Ben-Baruch G, Menczer J, Shalev J, et al. Uterine perforation during curettage: perforation rates and postperforation management. Isr J Med Sci 1980; 16:821.</a></li><li class="breakAll">Shulman LP, Elias S, Simpson JL. Induced abortion for genetic indications: techniques and complications. In: Genetic Disorders and the Fetus: Diagnosis, Prevention and Treatment, Milunsky A (Ed), Johns Hopkins University Press, Baltimore 1992. p.721.</li><li><a class="nounderline abstract_t">Thonneau P, Fougeyrollas B, Ducot B, et al. Complications of abortion performed under local anesthesia. Eur J Obstet Gynecol Reprod Biol 1998; 81:59.</a></li><li><a class="nounderline abstract_t">Wolman I, Gordon D, Yaron Y, et al. Transvaginal sonohysterography for the evaluation and treatment of retained products of conception. Gynecol Obstet Invest 2000; 50:73.</a></li><li><a class="nounderline abstract_t">Fielding WL, Lee SY, Borten M, Friedman EA. Continued pregnancy after failed first-trimester abortion. Obstet Gynecol 1984; 63:421.</a></li><li><a class="nounderline abstract_t">Burnhill MS, Armstead JW. Reducing the morbidity of vacuum aspiration abortion. Int J Gynaecol Obstet 1978-1979; 16:204.</a></li><li><a class="nounderline abstract_t">Kaunitz AM, Rovira EZ, Grimes DA, Schulz KF. Abortions that fail. Obstet Gynecol 1985; 66:533.</a></li><li><a class="nounderline abstract_t">Gürkan Zorlu C, Aral K, Ekici E, et al. Causative factors in first trimester abortion failure. Adv Contracept 1996; 12:63.</a></li><li><a class="nounderline abstract_t">Paul ME, Mitchell CM, Rogers AJ, et al. Early surgical abortion: efficacy and safety. Am J Obstet Gynecol 2002; 187:407.</a></li><li><a class="nounderline abstract_t">Edwards J, Creinin MD. Surgical abortion for gestations of less than 6 weeks. Curr Probl Obstet Gynecol Fertil 1997; 20:6.</a></li><li><a class="nounderline abstract_t">Edwards J, Carson SA. New technologies permit safe abortion at less than six weeks' gestation and provide timely detection of ectopic gestation. Am J Obstet Gynecol 1997; 176:1101.</a></li></ol></div><div id="topicVersionRevision">Topic 3287 Version 48.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32014520" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : A non-inferiority study of outpatient mifepristone-misoprostol medical abortion at 64-70 days and 71-77 days of gestation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32014520" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : A non-inferiority study of outpatient mifepristone-misoprostol medical abortion at 64-70 days and 71-77 days of gestation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32014520" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : A non-inferiority study of outpatient mifepristone-misoprostol medical abortion at 64-70 days and 71-77 days of gestation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32014520" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : A non-inferiority study of outpatient mifepristone-misoprostol medical abortion at 64-70 days and 71-77 days of gestation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32014520" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : A non-inferiority study of outpatient mifepristone-misoprostol medical abortion at 64-70 days and 71-77 days of gestation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21397086" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Prevention of infection after induced abortion: release date October 2010: SFP guideline 20102.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9647149" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : A randomised comparison of strategies for reducing infective complications of induced abortion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12118635" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Universal prophylaxis compared with screen-and-treat for Chlamydia trachomatis prior to termination of pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12118635" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Universal prophylaxis compared with screen-and-treat for Chlamydia trachomatis prior to termination of pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29794678" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : ACOG Practice Bulletin No. 195: Prevention of Infection After Gynecologic Procedures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29794678" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : ACOG Practice Bulletin No. 195: Prevention of Infection After Gynecologic Procedures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29794678" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : ACOG Practice Bulletin No. 195: Prevention of Infection After Gynecologic Procedures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22419307" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Perioperative antibiotics to prevent infection after first-trimester abortion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33346920" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Prophylactic antibiotics for preventing genital tract infection in women undergoing surgical procedures for incomplete abortion: a systematic review and meta-analysis of randomised controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22315257" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16816063" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Patient preferences, satisfaction, and resource use in office evacuation of early pregnancy failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16816063" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Patient preferences, satisfaction, and resource use in office evacuation of early pregnancy failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29946727" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Association of Facility Type With Procedural-Related Morbidities and Adverse Events Among Patients Undergoing Induced Abortions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22067751" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Women's preferences for pain control during first-trimester surgical abortion: a qualitative study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7556858" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Pain control in abortion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24309219" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Intramuscular ketorolac versus oral ibuprofen for pain relief in first-trimester surgical abortion: a randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19341852" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : First-trimester surgical abortion practices: a survey of National Abortion Federation members.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22525915" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Paracervical block for pain control in first-trimester surgical abortion: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19935022" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Paracervical block with combined ketorolac and lidocaine in first-trimester surgical abortion: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24983679" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Doula support during first-trimester surgical abortion: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27612588" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Doulas for surgical management of miscarriage and abortion: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26480890" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Women's experiences with doula support during first-trimester surgical abortion: a qualitative study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24633171" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : The impact of gentle language on pain perception during colposcopy: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22001664" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : An everyday phrase may harm your patients: the influence of negative words on pain during venous blood sampling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20042440" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Nocebo-induced hyperalgesia during local anesthetic injection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23090523" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Hydrocodone-acetaminophen for pain control in first-trimester surgical abortion: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19155895" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Oral compared with intravenous sedation for first-trimester surgical abortion: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26241254" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : An Evaluation of Oral Midazolam for Anxiety and Pain in First-Trimester Surgical Abortion: A Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28629738" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Nitrous oxide versus oral sedation for pain management of first-trimester surgical abortion - a randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27621048" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Nitrous oxide for pain management during in-office hysteroscopic sterilization: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27621048" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Nitrous oxide for pain management during in-office hysteroscopic sterilization: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27621048" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Nitrous oxide for pain management during in-office hysteroscopic sterilization: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14704252" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Manual versus electric vacuum aspiration for early first-trimester abortion: a controlled study of complication rates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18053098" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Manual versus electric vacuum aspiration for first-trimester abortion: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12618255" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Similarities in women's perceptions and acceptability of manual vacuum aspiration and electric vacuum aspiration for first trimester abortion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12618254" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Acceptability of manual versus electric aspiration for first trimester abortion: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6462569" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Human chorionic gonadotropin in maternal plasma after induced abortion, spontaneous abortion, and removed ectopic pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5749054" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Regulation of human gonadotropins. II. Disappearance of human chorionic gonadotropin following delivery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15051567" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Routine follow-up visits after first-trimester induced abortion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15051567" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Routine follow-up visits after first-trimester induced abortion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23773527" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : ONE KEY QUESTION®: Preventive reproductive health is part of high quality primary care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16199653" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : ACOG practice bulletin. Clinical management guidelines of obstetrician-gynecologists. Number 67, October 2005. Medical management of abortion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2359559" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Complications of first-trimester abortion: a report of 170,000 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2359559" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Complications of first-trimester abortion: a report of 170,000 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26238336" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Complications from first-trimester aspiration abortion: a systematic review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19888037" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Immediate complications after medical compared with surgical termination of pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34292926" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Sexually Transmitted Infections Treatment Guidelines, 2021.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23218863" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Management of postabortion hemorrhage: release date November 2012 SFP Guideline #20131.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18772098" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Complications after second trimester surgical and medical abortion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14745564" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : A survey of uterine perforation following dilatation and curettage or evacuation of retained products of conception.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7192698" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Uterine perforation during curettage: perforation rates and postperforation management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7192698" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Uterine perforation during curettage: perforation rates and postperforation management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9846716" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Complications of abortion performed under local anesthesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10965186" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Transvaginal sonohysterography for the evaluation and treatment of retained products of conception.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6700868" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Continued pregnancy after failed first-trimester abortion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33080" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Reducing the morbidity of vacuum aspiration abortion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4047543" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Abortions that fail.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8739517" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Causative factors in first trimester abortion failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12193934" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Early surgical abortion: efficacy and safety.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Surgical abortion for gestations of less than 6 weeks</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9166176" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : New technologies permit safe abortion at less than six weeks' gestation and provide timely detection of ectopic gestation.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
